top of page
Catheter Lab Image02d.jpg
Joe Knight_Head Shot.png

Joe Knight, PhD

Chief Executive Officer

Dr. Knight has 20 years of experience in medical device innovation and commercialization. He has been part of the intellectual property development, business, and strategic planning for multiple ventures, including iRhythm Technologies (NASDAQ: IRTC), Higgs Boson Health, and as Founder/CEO of Medici Medical Technologies. Before joining Simpson Interventions, Dr. Knight spent seven years as the President and CEO of InnAVasc Medical, until it was acquired by W. L. Gore & Associates. He spent five years at Medtronic in various marketing, business development, and strategy roles. He served as the European Marketing Manager in Switzerland, responsible for ensuring successful launch for four separate technologies related to the CoreValve/Engager product lines within 12+ individual countries in the European Union. In his last role with Medtronic, as the Director of Strategic Marketing, he developed and executed the strategy that led to Medtronic's $100M acquisition of CardioInsight. Dr. Knight is an Executive in Residence in the Department of Biomedical Engineering at Duke University where he teaches courses on medical device innovation. Early in his career, Dr. Knight served eight years as an infantry soldier in the U. S. Army, reaching the rank of Staff Sergeant and was awarded the Expert Infantryman's Badge (EIB), among the most prized peacetime decorations. Dr. Knight received a B.S. and M.S. in Engineering from the University of South Florida, an M.B.A. from the Fuqua School of Business at Duke University, a PhD in Biomedical Engineering from the Swiss Federal Institute of Technology Zurich and completed Stanford University's Biodesign Innovation Fellowship.


John B. Simpson, PhD, MD

Founder, Chairman & Chief Medical Officer

Dr. Simpson has revolutionized the field of medicine through a variety of innovations that have fundamentally altered how physicians treat cardiovascular disease. Dr. Simpson has started numerous companies dedicated to providing patients with the most cutting-edge therapies in a variety of different areas, including directional atherectomy (coronary and peripheral), chronic total occlusions (CTOs), ultrasound, percutaneous transluminal coronary angioplasty, suture-mediated vascular closure, and a local drug delivery. He received his PhD in Immunology from the University of Texas and his MD from Duke University School of Medicine. He completed his fellowship in interventional cardiology at Stanford University, is a member of the American College of Physicians, a fellow of American College of Cardiology, has been published on a wide variety of medical subjects, and has lectured extensively throughout the world. Dr. Simpson is the first American to receive the European Society of Cardiology Andreas Gruentzig award and a proud early recipient of the TCT lifetime achievement award. In 2019, he was awarded the Fritz J. and Dolores H. Russ Price by the National Academy of Engineering. ‍ Dr. Simpson is founder of Advanced Cardiovascular Systems (ACS, sold to NYSE:LLY, now part of NYSE:ABT), Devices for Vascular Intervention (DVI, sold to NYSE:LLY, now part of NYSE:ABT), Cardiovascular Imaging Systems Inc. (CVIS, sold to NYSE:BSX), Perclose (sold to NYSE:ABT, now part of NYSE:BSX), FoxHollow Technologies (sold to EV3, now part of NYSE:MDT), Avinger (NASDAQ:AVGR), and most recently Simpson Interventions. ‍ Today, he focuses his efforts towards developing devices aimed at radically improving the treatment of vascular disease through the expansion of new technologies and approaches such as optics, automation and software engineering.


Kin F. Chan, PhD

Co-founder & Chief Technology Officer

Dr. Chan is an experienced medtech entrepreneur with 20 years of industry experience in optics and biophotonics, biomedical engineering and biological sciences. He has contributed to significant advancement in medical optics and biomedical research in the areas of urology, cardiology and dermatology, addressing unmet needs in laser lithotripsy, laser aesthetics/dermatology, image-guided chronic total occlusion and atherectomy, topical drug delivery, and pharmacokinetics & pharmacodynamics tomography. He received his B.S., M.S., and Ph.D. in Electrical & Computer Engineering from the University of Texas at Austin, and was trained in electrical, computer, biomedical and laser & optical engineering. Dr. Chan is well-published in laser tissue interaction, ablation, fractional photothermolysis and other energy-based therapeutic devices and is a co-inventor on more than 30 issued patents or pending patent applications. He is a fellow of the International Society for Optics and Photonics (SPIE) and the American Society for Laser Medicine and Surgery (ASLMS). ‍ Prior to co-founding Simpson Interventions, he co-founded and was Executive VP of R&D of BioPharmX, (NYSE: BPMX; now NYSE: TMBR), was Vice President of Engineering at Demira (NASDAQ: DERM; now a subsidiary of NYSE: LLY) and Managing Director of Advanced Research at Solta Medical (formerly Reliant Technologies, Inc. - the Fraxel® laser; now a division of Bausch Health Company, NYSE:BHC). ‍ He is currently focusing on multi-disciplinary technological innovations and solutions in order to provide the best user experience for physicians and for optimal patient outcome.


Douglas Rowe

Vice President, Research and Development

Doug Rowe is a medical device engineer with over 20 years of experience in the industry. His industry experience ranges from the development of devices to treat Coronary Artery Disease, Peripheral Artery Disease to Vessel Closure.  ​ Prior to Simpson Interventions, he was Director of R&D at Atheromed Inc (Sold to NASDAQ:VOLC; now NYSE: PHG), Sr. R&D Engineer at XTENT Inc.  (NYSE: XTNT) and a Product Development Engineer at Perclose (sold to NYSE:ABT now part of NYSE: BSX). He received his B.S. in Mechanical Engineering from California Polytechnic State University, San Luis Obispo with a concentration on mechanical design and developed expertise on CNC machining. He is pushing the innovation envelope on catheter design with outside-of-the-box solutions in order to place intuitive and easy-to-use devices into the hands of physicians.



Simpson Interventions has assembled a team of scientists and engineers with cumulative experience well over a hundred years from the medical device industry in order to spearhead technology innovations and advancement with an emphasis on their ease-of-use into the hands of physicians and surgeons.

bottom of page